Cargando…

Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer

Introduction: The integration of diagnostic testing for the presence of a molecular target is of interest to predict successful targeted radionuclide therapy (TRNT). This so-called ‘theranostic’ approach aims to improve personalized treatment based on the molecular characteristics of cancer cells. M...

Descripción completa

Detalles Bibliográficos
Autores principales:	D’Huyvetter, Matthias, Xavier, Catarina, Caveliers, Vicky, Lahoutte, Tony, Muyldermans, Serge, Devoogdt, Nick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2014
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4245996/ https://www.ncbi.nlm.nih.gov/pubmed/25035968 http://dx.doi.org/10.1517/17425247.2014.941803

Ejemplares similares

Targeted Radionuclide Therapy with A (177)Lu-labeled Anti-HER2 Nanobody
por: D'Huyvetter, Matthias, et al.
Publicado: (2014)

Beyond the Barrier: Targeted Radionuclide Therapy in Brain Tumors and Metastases
por: Puttemans, Janik, et al.
Publicado: (2019)

Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle
por: Dekempeneer, Yana, et al.
Publicado: (2016)

Immunogenicity Risk Profile of Nanobodies
por: Ackaert, Chloé, et al.
Publicado: (2021)

Theranostics in immuno-oncology using nanobody derivatives
por: Lecocq, Quentin, et al.
Publicado: (2019)

Site-Specific Radiolabeling of a Human PD-L1 Nanobody via Maleimide–Cysteine Chemistry
por: Chigoho, Dora Mugoli, et al.
Publicado: (2021)

Specificity Evaluation and Disease Monitoring in Arthritis Imaging with Complement Receptor of the Ig superfamily targeting Nanobodies
por: Zheng, Fang, et al.
Publicado: (2016)

Preclinical Targeted α- and β(−)-Radionuclide Therapy in HER2-Positive Brain Metastasis Using Camelid Single-Domain Antibodies
por: Puttemans, Janik, et al.
Publicado: (2020)

The Road to Personalized Myeloma Medicine: Patient-specific Single-domain Antibodies for Anti-idiotypic Radionuclide Therapy
por: Puttemans, Janik, et al.
Publicado: (2022)

Assessment of mouse-specific pharmacokinetics in kidneys based on (131)I activity measurements using micro-SPECT
por: Vargas, Clarita Saldarriaga, et al.
Publicado: (2022)

Preclinical Evaluation of (225)Ac-Labeled Single-Domain Antibody for the Treatment of HER2(pos) Cancer
por: Rodak, Magdalena, et al.
Publicado: (2022)

A non-internalised CD38-binding radiolabelled single-domain antibody fragment to monitor and treat multiple myeloma
por: Duray, Elodie, et al.
Publicado: (2021)

A nanobody-based tracer targeting DPP6 for non-invasive imaging of human pancreatic endocrine cells
por: Balhuizen, Alexander, et al.
Publicado: (2017)

Development and Characterization of Nanobodies Targeting the Kupffer Cell
por: Zheng, Fang, et al.
Publicado: (2021)

Therapeutic Nanobodies Targeting Cell Plasma Membrane Transport Proteins: A High-Risk/High-Gain Endeavor
por: Van Campenhout, Raf, et al.
Publicado: (2021)

Nanobody-Based Theranostic Agents for HER2-Positive Breast Cancer: Radiolabeling Strategies
por: Hrynchak, Ivanna, et al.
Publicado: (2021)

Nanobodies for the Early Detection of Ovarian Cancer
por: Tran, Lan-Huong, et al.
Publicado: (2022)

Anti-Human PD-L1 Nanobody for Immuno-PET Imaging: Validation of a Conjugation Strategy for Clinical Translation
por: Bridoux, Jessica, et al.
Publicado: (2020)

(68)Ga-Labeling: Laying the Foundation for an Anti-Radiolytic Formulation for NOTA-sdAb PET Tracers
por: Baudhuin, Henri, et al.
Publicado: (2021)

Subcellular Targeting of Theranostic Radionuclides
por: Bavelaar, Bas M., et al.
Publicado: (2018)

Targeted Radionuclide Therapy with Low and High-Dose Lutetium-177–Labeled Single Domain Antibodies Induces Distinct Immune Signatures in a Mouse Melanoma Model
por: Ertveldt, Thomas, et al.
Publicado: (2022)

Identification of Nanobodies against the Acute Myeloid Leukemia Marker CD33
por: Romão, Ema, et al.
Publicado: (2020)

The Therapeutic Potential of Nanobodies
por: Jovčevska, Ivana, et al.
Publicado: (2019)

Nanobody-based pannexin1 channel inhibitors reduce inflammation in acute liver injury
por: Van Campenhout, Raf, et al.
Publicado: (2023)

Radiolabeling Strategies of Nanobodies for Imaging Applications
por: Küppers, Jim, et al.
Publicado: (2021)

A guide to: generation and design of nanobodies
por: Muyldermans, Serge
Publicado: (2020)

CS1-specific single-domain antibodies labeled with Actinium-225 prolong survival and increase CD8+ T cells and PD-L1 expression in Multiple Myeloma
por: De Veirman, Kim, et al.
Publicado: (2021)

Nanobody-Based Delivery Systems for Diagnosis and Targeted Tumor Therapy
por: Hu, Yaozhong, et al.
Publicado: (2017)

Imaging of Glioblastoma Tumor-Associated Myeloid Cells Using Nanobodies Targeting Signal Regulatory Protein Alpha
por: De Vlaminck, Karen, et al.
Publicado: (2021)

Nanobodies As Novel Agents for Targeting Angiogenesis in Solid Cancers
por: Arezumand, Roghaye, et al.
Publicado: (2017)

Radiolabeled theranostics: magnetic and gold nanoparticles
por: Same, Saeideh, et al.
Publicado: (2016)

Radiolabelled Aptamers for Theranostic Treatment of Cancer
por: Khalid, Umair, et al.
Publicado: (2018)

Advances in Radionuclides and Radiolabelled Peptides for Cancer Therapeutics
por: Chakraborty, Kushal, et al.
Publicado: (2023)

Targeted Nanobody-Based Molecular Tracers for Nuclear Imaging and Image-Guided Surgery
por: Debie, Pieterjan, et al.
Publicado: (2019)

Direct Immobilization of Engineered Nanobodies on Gold Sensors
por: Simões, Bárbara, et al.
Publicado: (2021)

Application of Single-Domain Antibodies (“Nanobodies”) to Laboratory Diagnosis
por: Pillay, Tahir S., et al.
Publicado: (2021)

Antibody and Nanobody Radiolabeling with Copper-64: Solid vs. Liquid Target Approach
por: Hrynchak, Ivanna, et al.
Publicado: (2023)

Phase I Study of [(68)Ga]Ga-Anti-CD206-sdAb for PET/CT Assessment of Protumorigenic Macrophage Presence in Solid Tumors (MMR Phase I)
por: Gondry, Odrade, et al.
Publicado: (2023)

Nanobodies and recombinant binders in cell biology
por: Helma, Jonas, et al.
Publicado: (2015)

Nanobodies targeting ABCC3 for immunotargeted applications in glioblastoma
por: Ruiz-López, Eduardo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ic2l6fs8bcdjrdjp1c9t1nkmj9